Clinical Trial

F-Tryptophan PET/CT in Human Cancers

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Imaging procedures such as 1-(2-\[18F\]FLUOROETHYL)-L-Tryptophan PET/CT in patients with cancers may help doctors assess a patient's response to treatment and help plan the best treatment in the future. The purpose is to see if there can be a better differentiation of tumor and non-tumor tissue where the tumor tissue has a higher uptake of Tryptophan.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-09-22; most recent amendment 2026-01-21.
Trial Details
NCT Number NCT05556473
Lead Sponsor Barbara Ann Karmanos Cancer Institute
Collaborators: Washington University School of Medicine
Conditions Intracranial Glioma, Metastatic Brain Tumor, Breast Cancer, Neuroendocrine Tumors, Rectal Cancer
Enrollment 24 participants
Start Date 2022-09-29
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-23